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The last decades have witnessed immense progress in
understanding the mechanistic links between risk factors for
atherosclerosis and the pathophysiology of atherothrombo-
sis. Processes such as inflammation and oxidation have
joined the traditional canon of risk factors that includes
hyperlipidemia, hypertension, and hypercoagulability. The
more we learn, the more overlap we appreciate in the
mechanisms that mediate the atherothrombotic risk of these
factors and processes.
Shared mechanisms link risk factors for atherosclerosis. Until
recently, for example, most viewed hypertension as a disor-
der of vasomotion and/or of salt and water balance. We now
appreciate that hypertension goes hand in hand with oxi-
dative stress. Most notably, angiotensin II potently regulates
the oxidases that give rise to the pro-oxidant species
superoxide anion (1). Hypertension also links to inflamma-
tion through innate and adaptive immunity. Angiotensin II
can stimulate production of cytokines such as interleukin-6
and monocyte chemotactic protein-1, and may augment the
recruitment of leukocytes to the artery wall (2,3). More
recent observations show the participation of adaptive im-
munity in hypertension, as T cells modulate the develop-
ment of hypertension in mice (4).
See page 1426
Moreover, the links between thrombosis and fibrinolysis
and inflammation have become ever more compelling (5).
Thrombin, in addition to its pro-coagulant properties, can
provoke the production and release of pro-inflammatory
cytokines from a variety of cell types involved in athero-
thrombosis. Inflammatory mediators, ultimately through
the mediation of interleukin-6, augment the hepatic pro-
duction of fibrinogen. The acute-phase inflammatory re-
sponse likewise boosts levels of the major endogenous
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Thus, in both hypertension and thrombosis, inflammation
provides a mechanism that explains the effects of the
classical risk factors on the arterial wall.
Oxidation of lipoproteins links lipids with oxidative
stress. Most schemata of atherogenesis posit a primary
role of oxidation of low-density lipoprotein (LDL) (6).
The wealth of pre-clinical evidence supporting this view,
and the relative weakness of competing concepts of the
initiation of atherogenesis, has rendered the oxidation
hypothesis of atherogenesis ascendant. The extrapolation
to human disease of this hypothesis, despite abundant
pre-clinical information and clinical associations, remains
incomplete (7). Yet, the previous discovery that lipopro-
tein(a) (Lp(a)) furnishes a “sink” for the oxidized phos-
pholipid components of oxidized lipoproteins opened a
new link between thrombosis and lipoproteins, as indi-
viduals with elevated Lp(a) have a heightened risk for
atherothrombotic events (8).
Oxidized lipids and atherothrombosis: a new link. In this
issue of the Journal, Leibundgut et al. (9) expand the links
between constituents of oxidized lipoproteins and the
mechanisms that underlie atherothrombosis. Lp(a) consists
of an LDL particle containing an apolipoprotein B mole-
cule, to which apolipoprotein(a) [apo(a)] has bound cova-
lently. Apo(a) contains multiple kringle repeats, a structural
motif shared by plasminogen. Indeed, clinical correlations
have long linked high levels of Lp(a) with heightened risk of
atherothrombotic events. The structural similarity between
apo(a) and plasminogen suggested to the La Jolla investi-
gators that, like Lp(a), plasminogen might also serve as a
“sink” for oxidized phospholipids in the blood compart-
ment. They present an elegant and broad series of experi-
ments in support of this innovative hypothesis. They used a
combination of biochemical and chemical techniques to
demonstrate that oxidized phospholipids bind to epsilon
amino groups of certain lysine residues in plasminogen by
forming Schiff bases. This covalent modification appears
peculiar to plasminogen, among the other kringle-
containing participants in coagulation and fibrinolysis.
The La Jolla team further probed the functional conse-
quences of this derivatization. They produced plasminogen
free of oxidized phospholipid by treatment with phospho-
lipase in vitro, and then examined the effect of both the
oxidized phospholipid-derivatized plasminogen and of un-
modified plasminogen on thrombolysis in vitro. Curiously,
they found that removal of the oxidized phospholipid
moiety actually prolonged the clot lysis time. That is, the
oxidative modification actually seems to promote the
thrombolytic potential of plasminogen. This in vitro assay,
while commonly used, may not extrapolate directly to
humans. Yet, if the modification of products of lipoprotein
oxidation of plasminogen enhanced its thrombolytic ability
in vivo, it would provide yet another example of an unex-
pected beneficial effect of a mechanism usually considered a
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more counterregulatory processes seem the rule rather than
the exception in the control of atherothrombosis, as in other
biological processes.
The La Jolla group translated their in vitro findings to
some pilot observations on patient-derived blood speci-
mens. In one of their key preliminary findings, they describe
an increase in the plasminogen derivatized by oxidized
phospholipid in the blood of individuals who have sustained
an acute coronary event. This rise in modified plasminogen
following acute coronary syndromes might augment fibrino-
lytic potential, if indeed the in vitro results presented pertain
to humans. Perhaps the well-known early peak in recurrent
events in the months following acute coronary syndromes
would be worse, were it not for this unexpected action of
plasminogen derivatized with oxidized phospholipids. Fur-
thermore, as the authors point out, the novel mechanisms
that they have uncovered might help to explain the increase
in experimental atherogenesis previously reported in mice
with loss of plasminogen function.
The yin and yang of atherothrombosis. The results re-
ported here situate in a broader context of counterregulatory
balances that apply to all major pathways implicated in
atherothrombosis (Fig. 1). In adaptive immunity, for exam-
ple, we now appreciate the tug of war between mediators
elaborated by T lymphocytes of the T helper 1 (Th1) versus
the T helper 2 (Th2) and regulatory T cell (Treg) subpopu-
ations (7). We also recognize that B1 lymphocytes can
meliorate atherogenesis, while B2 cells aggravate it. Hu-
oral immunity, as exemplified by antioxidized LDL anti-
odies, may mitigate atherogenesis. In the province of
nnate immunity, we now appreciate the participation of
ro-inflammatory populations of monocytes (those bearing
igh levels of the surface marker Ly6c in mice) and their less
nflammatory counterparts, and of pro-inflammatory classi-
ally activated M1 macrophages and alternatively activated
Figure 1 Schematic Depiction of Some Counterregulatory Mec
The text on the left lists risk factors for atherothrombosis; the processes denoted
thrombosis. The text on the right lists behaviors that may mitigate the risk for ath
some linked endogenous mechanisms that limit atherothrombotic risk. LDL  low2 macrophages in this disease (10).
rWe have long appreciated the balance between pro-
oagulants and fibrinolytics that operate in thrombogenesis
nd regulate clot stability. In the lipoprotein field, we have
ong observed the particularly pro-atherogenic effects of
ertain fractions of LDL, and the counterbalancing effects
f high levels of high-density lipoprotein in association with
he risk for atherothrombosis. We understand now that
ven modification by phospholipids can exert a counterregu-
atory effect in this context.
The deeper we dig, the less support we garner for our
nitially simplistic assumptions about the culprits and pro-
ectors in atherothrombotic risk. For most “yins,” a “yang”
rovides balance. Most pathophysiologic pathways have
lusses and minuses in the ultimate generation of clinical
vents. The more we probe, the more complexity emerges in
he web of links that intertwines our traditional rubrics of
ipids, oxidation, thrombosis, and inflammation. The
ouble-edged sword with which these processes cut, and the
inks that unite them, highlight the challenge we face in
nding new targets for interventions that will tip the overall
alance toward benefit. Our ever-growing recognition of
hese complexities indicates how our pre-clinical prejudices
nd experiments focused on one side of the scale may cause
s to underestimate the countervailing influences, and thus
ead us astray. Provocative observations such as those
resented by the La Jolla group remind us to check our
reconceptions at the door of experiment. We must resist
he urge to compact the rich and multidimensional com-
lexity of the biology of atherothrombosis into the narrow
pace of our personal preoccupations.
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